Accessible at: [Accessed 26th June 2025]
Semaglutide: new dawn for diabetics
Jehangir tracks your progress
To overcome these problems, various halogenated derivatives (e.g., chlorinated or boronated PBN), alkylated derivatives having a lipophilic tail (e.g., those with dodecyl chains), bifunctional derivatives (e.g., GS-PBN, Mito-DEPMPO, 5-ChEPMPO, DECPO, and 4-HMDEPMPO), conjugates with drugs or targeting molecules (such as PEG or heparin, that both can cross the BBB), dimers, and cyclodextrin polymers have been developed in the last few years (Han et al., 2009
PubMed laboratory research record [PMID: 31879547] PubMed record related to this compound for laboratory literature review
GLP-1 drugs likely to be helpful for additional indications October 22, 2025 Summary: New GLP-1 and related drugs are likely to become available over the next 3-5 years, and this drug class will likely be approved for additional indications